Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna stock has bounced off its 52-week low but still looks incredibly weak.

Moderna Stock Looks Sick; Here's How To Take Advantage With Options

U.S. vaccine maker Moderna began construction of its first facility in China this month to manufacture mRNA medicines, the company said on Tuesday.

Moderna begins work on China mRNA manufacturing site

BioNTech SE

Moderna and BioNTech are pioneering companies in mRNA technology, known for their fast development of highly effective COVID-19 vaccines. Both companies have the potential to transform the treatment landscape for various diseases, including cancer and infectious diseases. Both companies hold late-stage assets that pave the road for near-term growth.

BioNTech Vs. Moderna: Navigating The mRNA Landscape

Axsome Therapeutics

CRISPR Therapeutics

There are several paths to millionaire status, and investing is one of them. But to give yourself a chance to become a millionaire this way, it's important to buy a diverse basket of solid companies and hold onto those shares for the long term.

3 Biotech Stocks That Could Be Millionaire Makers

Moderna Inc shares slipped nearly 4% to $76.06 in early trading on Tuesday after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, Reuters reported.  The media outlet noted the ruling is a victory for BioNTech and its partner Pfizer in a patent dispute between the biggest coronavirus vaccine makers.

Moderna stock falls as mRNA patent called ‘invalid' by European Patent Office

COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer.

BioNTech says European Patent Office has declared Moderna patent invalid

Chevron

DTE Energy

Most of the earnings reports are in for the third quarter. But a contrarian play based on the results to date could actually be investment opportunities.

Don't Let the Q3 Earnings Miss Keep You From These 3 Stocks!

Moderna experienced a significant decline in Q3 2023 revenue, primarily due to a slump in COVID-19 vaccine sales. The company incurred substantial costs, including inventory write-downs and manufacturing wind-downs. The stock price is nearing a significant support level and exhibiting indications of reversing from this point.

Moderna Nears Key Technical Level With Indications Of Reversal (Rating Upgrade)

Moderna reported $1.8 billion in revenue, beating estimates, but recorded a massive GAAP earnings-per-share loss. Wall Street analysts lowered price targets for Moderna stock following the lackluster quarter. Moderna's Spikevax vaccine sales are expected to decline in 2024, but the company plans to introduce new vaccines to drive future revenue growth.

Investing In Moderna: A Calculated Risk Worth Taking For Patient Investors

Moderna, Inc. (NASDAQ:MRNA ) 2023 Jefferies London Healthcare Conference November 16, 2023 3:30 AM ET Company Participants Lavina Talukdar - Senior Vice president of Investor Relations Conference Call Participants Unidentified Analyst Good morning everyone. Thank you for joining us here on our opening morning session for Moderna.

Moderna, Inc. (MRNA) 2023 Jefferies London Healthcare Conference Transcript

Is Moderna stock a sell after its initial 2024 sales guidance widely misses expectations? Is MRNA stock a sell right now?

Is Moderna Stock A Sell After Its Sales Guidance Undercuts 2024 Expectations?

CAMBRIDGE, MA / ACCESSWIRE / November 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023.

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023

Ginkgo Bioworks Holdings

Intuitive Surgical

Cathie Wood loves to pick up shares of innovators while they're down -- because she counts on gains over time. Wood's flagship exchange-traded fund is outperforming the S&P 500 so far this year.

3 Cathie Wood Bargain Buys That Should Be on Your List Too

Moderna, Inc. (NASDAQ:MRNA ) Second Digital Investor Event November 8, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of IR Stephane Bancel - CEO Brad Miller - Chief Information Officer Dave Johnson - Chief Data and Artificial Intelligence Officer Wenhao Liu - Director of Software Engineering Brice Challamel - Empowerment VP Conference Call Participants Hartaj Singh - Oppenheimer & Co. Jasmine Fels - UBS Jessica Fye - JP Morgan Lavina Talukdar Good morning, everyone, and welcome to Moderna's Second Digital Investor Event. Since our first digital event in early 2020, we have made great progress in our digital strategy and the role of AI in accelerating innovation, scale and value creation at Moderna.

Moderna, Inc. (MRNA) Second Digital Investor Event Transcript

Amgen

Amgen's new acquisition, deep pipeline, and solid dividend profile make it a solid long-term pick. Moderna hopes to replace revenue from its coronavirus vaccine by earning new approvals.

2 Top Biotech Stocks to Buy Right Now

Several analysts cut their price targets on the once-hotly popular biotech. Moderna is known for its Spikevax coronavirus vaccine.

Why Moderna Stock Was Cratering This Week

Moderna's stock hasn't done well lately now that coronavirus vaccine sales are falling. But the biotech has an ambitious plan to launch over a dozen medicines relatively soon.

Moderna's Stock Just Tumbled 12%. Here's Why It's Still a Buy.

Salesforce

NVIDIA

Bristol-Myers

Crown Castle International

Citizens Financial Group

Comerica

Eversource Energy

KeyCorp

Pfizer

Charles Schwab

J. M. Smucker

Truist Financial

Tapestry

Walgreens

Stocks' yearly performance rankings are a field day for contrarians: One year's worst often are the subsequent year's best, and vice versa.

Why this Dow stock went from worst in 2022 to first in 2023 — and 13 turnaround candidates for 2024

CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 2023 UBS Global Biopharma Conference on November 9th at 8:00 a.m. ET. 2023 Jefferies London Healthcare Conference on November 16th at 8:30 a.m.

Moderna to Present at Upcoming Conferences in November 2023

Enphase Energy

Illumina

JD.com

Sirius XM Holdings Inc

One knock against Wall Street analysts is they're too bullish, especially when it comes to Nasdaq 100 stocks. No matter the market conditions, they seem able to find the silver lining.

6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%

The Company demonstrates how its integrated Artificial Intelligence ecosystem accelerates innovation at scale and creates value across the enterprise Moderna to present case studies on how the organization is building a real-time AI Company CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off its Manufacturing and Digital Day hosted in March 2020, the Company will showcase how AI continues to transform the organization and enhance its value creation.

Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event

DraftKings

Digital Realty Trust

Duolingo

Paramount Global

Royal Caribbean Cruises

Snap

Investors face a complicated picture heading into the holiday season. War, inflation, high interest rates, and a potential recession are among the risk factors on the horizon.

High Risk Alert: 7 Vulnerable Stocks to Dump Now

CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year. "We are proud to be named the best place to work on BioSpace's 2024 ranking for the third year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Tops BioSpace's Best Places to Work Ranking for Third Consecutive Year

Cathie Wood is known for buying a stock when everyone else is selling it -- as long as the company's long-term prospects look good. Wood favors holding on for the long term, so she isn't bothered by short-term price moves.

Cathie Wood Just Bought This Struggling Stock After Its Billion-Dollar Quarterly Loss. Should You?

Moderna recently reported third-quarter results. The stock is down about 84% from its peak in 2021.

News for Moderna Stock (MRNA)